Fate Therapeutics (FATE) Receivables (2015 - 2026)

Fate Therapeutics (FATE) has 10 years of Receivables data on file, last reported at $704000.0 in Q1 2026.

• Quarterly Receivables fell 70.74% year-over-year to $704000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $704000.0 (down 70.74% YoY) and the FY2025 annual result came in at $916000.0, down 74.12% from the prior year.
• Receivables eased to $704000.0 in Q1 2026, from $916000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $38.5 million in Q4 2022 to a low of $682000.0 in Q3 2025.
• A 5-year average of $6.5 million and a median of $2.4 million in 2025 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables soared 343.52% — and 2023, when it plunged 95.25%.
• Tracing FATE's Receivables over 5 years: stood at $38.5 million in 2022, then sank by 95.25% to $1.8 million in 2023, then surged by 93.81% to $3.5 million in 2024, then slumped by 74.12% to $916000.0 in 2025, then fell by 23.14% to $704000.0 in 2026.
• The last three Receivables figures came in at $704000.0 (Q1 2026), $916000.0 (Q4 2025), and $682000.0 (Q3 2025), per Business Quant data.